vs
Side-by-side financial comparison of Ares Commercial Real Estate Corp (ACRE) and Autolus Therapeutics plc (AUTL). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $13.2M, roughly 1.6× Ares Commercial Real Estate Corp). Ares Commercial Real Estate Corp runs the higher net margin — -29.2% vs -373.3%, a 344.1% gap on every dollar of revenue.
Ares Commercial Real Estate Corp is a specialty finance company focused on the commercial real estate sector. It offers a full suite of customized financing solutions including senior mortgage loans, subordinated debt and preferred equity, primarily serving middle-market commercial property owners and operators across the United States.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
ACRE vs AUTL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.2M | $21.2M |
| Net Profit | $-3.9M | $-79.1M |
| Gross Margin | — | — |
| Operating Margin | -29.2% | -337.9% |
| Net Margin | -29.2% | -373.3% |
| Revenue YoY | -24.5% | — |
| Net Profit YoY | 63.8% | 3.6% |
| EPS (diluted) | — | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.2M | — | ||
| Q3 25 | $14.1M | $21.2M | ||
| Q2 25 | $12.6M | $20.9M | ||
| Q1 25 | $14.9M | $9.0M | ||
| Q4 24 | $17.5M | — | ||
| Q3 24 | $16.7M | $0 | ||
| Q2 24 | $16.8M | $0 | ||
| Q1 24 | $18.7M | $10.1M |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $4.7M | $-79.1M | ||
| Q2 25 | $-11.0M | $-47.9M | ||
| Q1 25 | $9.3M | $-70.2M | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-5.9M | $-82.1M | ||
| Q2 24 | $-6.1M | $-58.3M | ||
| Q1 24 | $-12.3M | $-52.7M |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | -337.9% | ||
| Q2 25 | -87.8% | -292.6% | ||
| Q1 25 | 64.4% | -726.3% | ||
| Q4 24 | -61.0% | — | ||
| Q3 24 | -35.3% | — | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | -384.1% |
| Q4 25 | -29.2% | — | ||
| Q3 25 | 33.0% | -373.3% | ||
| Q2 25 | -87.8% | -229.0% | ||
| Q1 25 | 62.5% | -781.1% | ||
| Q4 24 | -60.9% | — | ||
| Q3 24 | -35.3% | — | ||
| Q2 24 | -36.5% | — | ||
| Q1 24 | -65.9% | -522.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.30 | ||
| Q2 25 | — | $-0.18 | ||
| Q1 25 | — | $-0.26 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.31 | ||
| Q2 24 | — | $-0.22 | ||
| Q1 24 | — | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $29.3M | $86.1M |
| Total DebtLower is stronger | $948.2M | — |
| Stockholders' EquityBook value | $509.6M | $265.5M |
| Total Assets | $1.6B | $661.9M |
| Debt / EquityLower = less leverage | 1.86× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.3M | — | ||
| Q3 25 | $84.9M | $86.1M | ||
| Q2 25 | $90.0M | $123.8M | ||
| Q1 25 | $125.5M | $95.8M | ||
| Q4 24 | $63.8M | — | ||
| Q3 24 | $68.9M | $657.1M | ||
| Q2 24 | $70.6M | $705.9M | ||
| Q1 24 | $99.5M | $758.5M |
| Q4 25 | $948.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $718.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $509.6M | — | ||
| Q3 25 | $521.0M | $265.5M | ||
| Q2 25 | $523.7M | $346.5M | ||
| Q1 25 | $542.1M | $371.1M | ||
| Q4 24 | $540.1M | — | ||
| Q3 24 | $563.8M | $477.0M | ||
| Q2 24 | $582.3M | $527.8M | ||
| Q1 24 | $601.1M | $582.0M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.4B | $661.9M | ||
| Q2 25 | $1.4B | $721.0M | ||
| Q1 25 | $1.5B | $746.3M | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.9B | $827.5M | ||
| Q2 24 | $2.1B | $853.6M | ||
| Q1 24 | $2.1B | $901.4M |
| Q4 25 | 1.86× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.33× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.4M | $-67.9M |
| Free Cash FlowOCF − Capex | — | $-72.3M |
| FCF MarginFCF / Revenue | — | -341.2% |
| Capex IntensityCapex / Revenue | — | 20.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-322.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.4M | — | ||
| Q3 25 | $3.8M | $-67.9M | ||
| Q2 25 | $4.9M | $-72.8M | ||
| Q1 25 | $8.0M | $-75.6M | ||
| Q4 24 | $35.5M | — | ||
| Q3 24 | $8.4M | $-76.7M | ||
| Q2 24 | $8.7M | $-51.1M | ||
| Q1 24 | $11.4M | $-40.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-72.3M | ||
| Q2 25 | — | $-80.1M | ||
| Q1 25 | — | $-83.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-86.3M | ||
| Q2 24 | — | $-51.9M | ||
| Q1 24 | — | $-41.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | -341.2% | ||
| Q2 25 | — | -382.6% | ||
| Q1 25 | — | -933.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -406.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 20.8% | ||
| Q2 25 | — | 34.8% | ||
| Q1 25 | — | 91.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 5.3% |
| Q4 25 | — | — | ||
| Q3 25 | 0.82× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
